| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 24 | 2020 | 200 | 6.820 |
Why?
|
| Antineoplastic Agents | 15 | 2020 | 607 | 3.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2020 | 461 | 2.760 |
Why?
|
| Salvage Therapy | 4 | 2019 | 134 | 1.410 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2019 | 104 | 1.340 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2020 | 94 | 1.160 |
Why?
|
| Cytarabine | 7 | 2020 | 55 | 1.150 |
Why?
|
| Apoptosis | 8 | 2019 | 354 | 1.090 |
Why?
|
| Fluorodeoxyuridylate | 3 | 2016 | 23 | 1.050 |
Why?
|
| Neoplasms | 3 | 2018 | 692 | 1.050 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2017 | 44 | 1.040 |
Why?
|
| Sulfides | 6 | 2019 | 27 | 1.030 |
Why?
|
| Caprylates | 6 | 2019 | 28 | 1.030 |
Why?
|
| Enzyme Inhibitors | 3 | 2020 | 165 | 1.020 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2014 | 79 | 0.920 |
Why?
|
| Bone Marrow | 3 | 2020 | 70 | 0.880 |
Why?
|
| Mitochondria | 4 | 2019 | 186 | 0.830 |
Why?
|
| Cell Membrane | 1 | 2020 | 96 | 0.690 |
Why?
|
| Aged | 22 | 2020 | 10340 | 0.660 |
Why?
|
| Humans | 36 | 2020 | 32025 | 0.650 |
Why?
|
| Mice, Inbred C57BL | 7 | 2017 | 766 | 0.640 |
Why?
|
| Middle Aged | 21 | 2020 | 11868 | 0.620 |
Why?
|
| Body Composition | 1 | 2020 | 396 | 0.610 |
Why?
|
| Resuscitation Orders | 1 | 2017 | 13 | 0.600 |
Why?
|
| Glycerophosphates | 1 | 2017 | 4 | 0.600 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2014 | 24 | 0.590 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2019 | 370 | 0.580 |
Why?
|
| Deoxycytidine | 1 | 2017 | 68 | 0.580 |
Why?
|
| Intensive Care Units | 1 | 2017 | 110 | 0.560 |
Why?
|
| Neoplasm Proteins | 2 | 2014 | 148 | 0.560 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2019 | 17 | 0.560 |
Why?
|
| Leukemia | 2 | 2014 | 40 | 0.550 |
Why?
|
| Nucleosides | 1 | 2016 | 10 | 0.540 |
Why?
|
| Female | 23 | 2020 | 19954 | 0.530 |
Why?
|
| Survival Rate | 7 | 2020 | 885 | 0.520 |
Why?
|
| DNA Topoisomerases, Type I | 2 | 2012 | 9 | 0.520 |
Why?
|
| Thymidylate Synthase | 2 | 2012 | 14 | 0.520 |
Why?
|
| Animals | 12 | 2018 | 7466 | 0.510 |
Why?
|
| Mice | 9 | 2018 | 2475 | 0.500 |
Why?
|
| Cytogenetics | 1 | 2015 | 7 | 0.500 |
Why?
|
| Male | 22 | 2020 | 19196 | 0.500 |
Why?
|
| Fas Ligand Protein | 1 | 2014 | 7 | 0.500 |
Why?
|
| Membrane Microdomains | 1 | 2014 | 21 | 0.490 |
Why?
|
| Hydroxamic Acids | 1 | 2014 | 21 | 0.490 |
Why?
|
| Prognosis | 9 | 2020 | 1505 | 0.480 |
Why?
|
| Lipids | 1 | 2016 | 229 | 0.480 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 35 | 0.470 |
Why?
|
| Pyrimidines | 1 | 2014 | 65 | 0.470 |
Why?
|
| DNA Damage | 4 | 2017 | 98 | 0.460 |
Why?
|
| Azacitidine | 1 | 2013 | 28 | 0.460 |
Why?
|
| Mitoxantrone | 3 | 2019 | 19 | 0.460 |
Why?
|
| Remission Induction | 5 | 2020 | 84 | 0.450 |
Why?
|
| Aged, 80 and over | 9 | 2020 | 4000 | 0.440 |
Why?
|
| Adult | 13 | 2020 | 9367 | 0.430 |
Why?
|
| Oncogene Proteins | 1 | 2012 | 6 | 0.420 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2012 | 24 | 0.420 |
Why?
|
| Treatment Outcome | 8 | 2020 | 3317 | 0.420 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2012 | 41 | 0.420 |
Why?
|
| DNA Methylation | 1 | 2013 | 140 | 0.420 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 85 | 0.410 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 71 | 0.410 |
Why?
|
| Disease Models, Animal | 5 | 2014 | 1017 | 0.390 |
Why?
|
| Tandem Repeat Sequences | 1 | 2011 | 6 | 0.380 |
Why?
|
| Leukemia, Myeloid | 1 | 2011 | 24 | 0.380 |
Why?
|
| Membrane Proteins | 1 | 2012 | 257 | 0.370 |
Why?
|
| Cell Line, Tumor | 5 | 2017 | 725 | 0.370 |
Why?
|
| Aniline Compounds | 2 | 2020 | 18 | 0.360 |
Why?
|
| Geriatric Assessment | 4 | 2020 | 391 | 0.360 |
Why?
|
| Prospective Studies | 7 | 2020 | 2283 | 0.350 |
Why?
|
| Doxorubicin | 3 | 2017 | 82 | 0.330 |
Why?
|
| Recurrence | 3 | 2019 | 265 | 0.310 |
Why?
|
| Mutation | 2 | 2020 | 488 | 0.300 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 2280 | 0.290 |
Why?
|
| Survival Analysis | 4 | 2020 | 488 | 0.280 |
Why?
|
| Pancreatic Neoplasms | 2 | 2019 | 140 | 0.280 |
Why?
|
| Retrospective Studies | 6 | 2018 | 3523 | 0.280 |
Why?
|
| Adenocarcinoma | 2 | 2019 | 311 | 0.260 |
Why?
|
| Neoplasm Transplantation | 2 | 2017 | 73 | 0.250 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 456 | 0.250 |
Why?
|
| Age Factors | 4 | 2018 | 1194 | 0.240 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 273 | 0.230 |
Why?
|
| Mice, Transgenic | 2 | 2017 | 261 | 0.230 |
Why?
|
| RNA Polymerase II | 1 | 2003 | 1 | 0.220 |
Why?
|
| Transcriptional Elongation Factors | 1 | 2003 | 1 | 0.220 |
Why?
|
| Genes, Regulator | 1 | 2003 | 5 | 0.220 |
Why?
|
| Guanosine Triphosphate | 1 | 2003 | 8 | 0.220 |
Why?
|
| International Agencies | 2 | 2019 | 10 | 0.220 |
Why?
|
| Comorbidity | 5 | 2018 | 569 | 0.210 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 137 | 0.210 |
Why?
|
| Electron Transport | 2 | 2019 | 16 | 0.200 |
Why?
|
| RNA, Messenger | 1 | 2003 | 508 | 0.190 |
Why?
|
| Hyperglycemia | 2 | 2018 | 85 | 0.190 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2020 | 7 | 0.180 |
Why?
|
| Benzimidazoles | 1 | 2020 | 28 | 0.180 |
Why?
|
| Pyrazines | 1 | 2019 | 13 | 0.180 |
Why?
|
| Young Adult | 2 | 2018 | 2615 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 34 | 0.170 |
Why?
|
| Heme | 1 | 2019 | 61 | 0.160 |
Why?
|
| Cell Proliferation | 2 | 2018 | 599 | 0.160 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2018 | 9 | 0.160 |
Why?
|
| Citric Acid Cycle | 1 | 2018 | 11 | 0.160 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 565 | 0.160 |
Why?
|
| Protein Biosynthesis | 1 | 2018 | 40 | 0.160 |
Why?
|
| Cell Respiration | 1 | 2018 | 22 | 0.150 |
Why?
|
| Retreatment | 1 | 2018 | 41 | 0.150 |
Why?
|
| HL-60 Cells | 2 | 2014 | 14 | 0.150 |
Why?
|
| Proportional Hazards Models | 3 | 2015 | 757 | 0.150 |
Why?
|
| Philadelphia Chromosome | 1 | 2017 | 4 | 0.150 |
Why?
|
| Protein Kinase C | 1 | 2017 | 31 | 0.150 |
Why?
|
| Tumor Burden | 1 | 2017 | 60 | 0.150 |
Why?
|
| Hematologic Diseases | 1 | 2017 | 24 | 0.150 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2017 | 58 | 0.150 |
Why?
|
| Oxygen Consumption | 1 | 2018 | 154 | 0.140 |
Why?
|
| Patient Transfer | 1 | 2017 | 44 | 0.140 |
Why?
|
| Splenomegaly | 1 | 2016 | 7 | 0.140 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 9 | 0.140 |
Why?
|
| Cell Line | 1 | 2018 | 435 | 0.140 |
Why?
|
| Biopsy | 1 | 2018 | 260 | 0.140 |
Why?
|
| Cosmic Radiation | 1 | 2016 | 14 | 0.140 |
Why?
|
| Random Allocation | 1 | 2017 | 220 | 0.140 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2016 | 17 | 0.140 |
Why?
|
| DNA, Neoplasm | 2 | 2013 | 55 | 0.140 |
Why?
|
| Radiation Injuries | 1 | 2016 | 72 | 0.140 |
Why?
|
| Biological Availability | 1 | 2016 | 21 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 2 | 2016 | 168 | 0.130 |
Why?
|
| Blood Glucose | 1 | 2018 | 492 | 0.130 |
Why?
|
| Asparaginase | 1 | 2015 | 5 | 0.130 |
Why?
|
| Depression | 2 | 2016 | 443 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 629 | 0.130 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 259 | 0.130 |
Why?
|
| Transplantation, Homologous | 1 | 2015 | 151 | 0.120 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2014 | 12 | 0.120 |
Why?
|
| Ribonucleotide Reductases | 1 | 2014 | 6 | 0.120 |
Why?
|
| Cognition | 2 | 2016 | 553 | 0.120 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 62 | 0.120 |
Why?
|
| Lung | 1 | 2016 | 255 | 0.120 |
Why?
|
| Polypharmacy | 1 | 2014 | 17 | 0.120 |
Why?
|
| Oligonucleotides | 1 | 2014 | 30 | 0.120 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2014 | 100 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 168 | 0.120 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 2 | 2011 | 8 | 0.120 |
Why?
|
| Drug Evaluation | 1 | 2013 | 14 | 0.120 |
Why?
|
| Stem Cells | 1 | 2016 | 313 | 0.120 |
Why?
|
| Occupational Exposure | 1 | 2016 | 233 | 0.110 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 163 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2015 | 355 | 0.110 |
Why?
|
| Hospitalization | 2 | 2018 | 470 | 0.110 |
Why?
|
| Gene Fusion | 1 | 2012 | 2 | 0.110 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2012 | 5 | 0.110 |
Why?
|
| Translocation, Genetic | 1 | 2012 | 20 | 0.110 |
Why?
|
| Phenotype | 1 | 2015 | 639 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2012 | 8 | 0.110 |
Why?
|
| DNA Replication | 1 | 2012 | 34 | 0.110 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 51 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2012 | 49 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 300 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 409 | 0.100 |
Why?
|
| Trans-Activators | 1 | 2012 | 46 | 0.100 |
Why?
|
| Histones | 1 | 2012 | 53 | 0.100 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2012 | 22 | 0.100 |
Why?
|
| Substrate Specificity | 1 | 2012 | 87 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 114 | 0.100 |
Why?
|
| Transcription Factors | 1 | 2012 | 180 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 835 | 0.100 |
Why?
|
| Benzenesulfonates | 1 | 2011 | 3 | 0.100 |
Why?
|
| Gene Duplication | 1 | 2011 | 5 | 0.100 |
Why?
|
| Phenylurea Compounds | 1 | 2011 | 10 | 0.100 |
Why?
|
| Niacinamide | 1 | 2011 | 8 | 0.100 |
Why?
|
| Signal Transduction | 1 | 2014 | 687 | 0.090 |
Why?
|
| Pyridines | 1 | 2011 | 76 | 0.090 |
Why?
|
| RNA Interference | 1 | 2011 | 76 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 261 | 0.090 |
Why?
|
| Blotting, Western | 1 | 2011 | 292 | 0.090 |
Why?
|
| Acute Disease | 1 | 2011 | 254 | 0.090 |
Why?
|
| Risk Factors | 2 | 2015 | 3869 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 918 | 0.080 |
Why?
|
| Time Factors | 1 | 2015 | 2152 | 0.080 |
Why?
|
| Leucovorin | 2 | 2019 | 25 | 0.080 |
Why?
|
| Fluorouracil | 2 | 2019 | 82 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 1125 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 1428 | 0.070 |
Why?
|
| Macromolecular Substances | 1 | 2003 | 17 | 0.060 |
Why?
|
| Molecular Weight | 1 | 2003 | 41 | 0.060 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2003 | 20 | 0.060 |
Why?
|
| Binding Sites | 1 | 2003 | 130 | 0.050 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2012 | 17 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 147 | 0.050 |
Why?
|
| DNA | 1 | 2003 | 228 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 72 | 0.050 |
Why?
|
| Daunorubicin | 1 | 2020 | 27 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 319 | 0.040 |
Why?
|
| Electron Transport Chain Complex Proteins | 1 | 2019 | 8 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 11 | 0.040 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2019 | 17 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 182 | 0.040 |
Why?
|
| Mitochondrial Membranes | 1 | 2019 | 21 | 0.040 |
Why?
|
| Transduction, Genetic | 1 | 2019 | 42 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2019 | 67 | 0.040 |
Why?
|
| Lymphopenia | 1 | 2017 | 12 | 0.040 |
Why?
|
| Hypokalemia | 1 | 2017 | 14 | 0.040 |
Why?
|
| Neutropenia | 1 | 2017 | 30 | 0.040 |
Why?
|
| Hypoalbuminemia | 1 | 2017 | 12 | 0.040 |
Why?
|
| Sensation Disorders | 1 | 2017 | 20 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 31 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 61 | 0.040 |
Why?
|
| Camptothecin | 1 | 2017 | 52 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 47 | 0.040 |
Why?
|
| Abdominal Pain | 1 | 2017 | 45 | 0.040 |
Why?
|
| Body Burden | 1 | 2016 | 7 | 0.040 |
Why?
|
| Astronauts | 1 | 2016 | 8 | 0.040 |
Why?
|
| Anemia | 1 | 2017 | 59 | 0.040 |
Why?
|
| Topotecan | 1 | 2016 | 17 | 0.040 |
Why?
|
| Radiation Dosage | 1 | 2016 | 81 | 0.030 |
Why?
|
| Liver | 1 | 2019 | 483 | 0.030 |
Why?
|
| Genome, Human | 1 | 2016 | 132 | 0.030 |
Why?
|
| Physical Examination | 1 | 2016 | 92 | 0.030 |
Why?
|
| Sepsis | 1 | 2017 | 158 | 0.030 |
Why?
|
| Mental Health | 1 | 2016 | 115 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2016 | 188 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 411 | 0.030 |
Why?
|
| Survivors | 1 | 2016 | 159 | 0.030 |
Why?
|
| Mobility Limitation | 1 | 2016 | 219 | 0.030 |
Why?
|
| Logistic Models | 1 | 2015 | 781 | 0.030 |
Why?
|
| Affective Symptoms | 1 | 2013 | 16 | 0.030 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 2012 | 2 | 0.030 |
Why?
|
| Thymine | 1 | 2012 | 6 | 0.030 |
Why?
|
| S Phase | 1 | 2012 | 15 | 0.030 |
Why?
|
| Alkaloids | 1 | 2012 | 9 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2013 | 63 | 0.030 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2012 | 21 | 0.030 |
Why?
|
| Nursing Assessment | 1 | 2011 | 11 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 687 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 292 | 0.020 |
Why?
|
| Motor Activity | 1 | 2013 | 325 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 878 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2011 | 240 | 0.020 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2009 | 8 | 0.020 |
Why?
|
| Genes, ras | 1 | 2009 | 25 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2009 | 16 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2009 | 261 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 323 | 0.020 |
Why?
|
| Genotype | 1 | 2009 | 734 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2011 | 1831 | 0.020 |
Why?
|
| North Carolina | 1 | 2011 | 1516 | 0.020 |
Why?
|